Recent Highlights Exhibit 99.1 Kura Oncology Reports First Quarter 2024 Financial Results – Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – First patient dosed with KO-2806 and cabozantinib in renal cell carcinoma – – $527 million in cash, cash equivalents and investments provide ru ...

– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, ziftomenib, has been gra ...

Financial Data and Key Metrics Changes - Research and development (R&D) expenses for Q4 2023 were $32.5 million, up from $22.7 million in Q4 2022, while full-year R&D expenses increased to $115.2 million from $92.8 million year-over-year [21][22]. - Net loss for Q4 2023 was $42.8 million compared to a net loss of $33.1 million in Q4 2022, with a full-year net loss of $152.6 million versus $135.8 million in the prior year [22]. - As of December 31, 2023, cash, cash equivalents, and short-term investments totaled $424 million, down from $438 million a year earlier, but increased to approximately $570 million after a private placement in January 2024 [23]. Business Line Data and Key Metrics Changes - Ziftomenib demonstrated a 100% complete remission (CR) rate among five newly diagnosed patients with adverse risk acute myeloid leukemia (AML) and a 53% overall response rate (ORR) among 15 relapsed refractory patients [8][10]. - The company is advancing Ziftomenib in multiple studies, including KOMET-001 and KOMET-008, with plans to initiate a Phase 1b dose validation expansion by mid-2024 [14][25]. Market Data and Key Metrics Changes - The company is focusing on the NPM1 mutant and KMT2A rearranged AML markets, which represent significant unmet medical needs, particularly in pediatric populations [14][15]. - There is a growing interest in Ziftomenib among investigators, as evidenced by rapid enrollment in ongoing studies [13]. Company Strategy and Development Direction - The company aims to position Ziftomenib as a cornerstone therapy for acute leukemias driven by the Menin pathway, with plans to explore its use in solid tumors and other indications [16][78]. - Kura Oncology is also developing KO-2806, a next-generation Farnesyl Transferase Inhibitor, to enhance antitumor activity and address resistance mechanisms [17][19]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the safety and tolerability profile of Ziftomenib, highlighting its potential to become a preferred treatment option in the competitive AML market [62]. - The company anticipates completing enrollment in the KOMET-001 trial by mid-2024 and is preparing for pivotal studies based on the data generated [25][91]. Other Important Information - The company has initiated a proof-of-concept study for Ziftomenib in solid tumors and is making progress on a next-generation Menin inhibitor [16][78]. - Kura Oncology is actively engaging with global health authorities to expedite the development of its therapies [82]. Q&A Session Summary Question: Can you discuss your thoughts on the combinability of Ziftomenib with Ven/Aza? - Management confirmed that Ziftomenib is neither a CYP3A4 substrate nor an inhibitor, meaning no dose adjustment for Venetoclax is necessary when combined with Ziftomenib [29][32]. Question: What are the expectations for moving patients off Ziftomenib therapy? - Management indicated that patients are expected to remain on Ziftomenib until disease progression, with potential breaks only for transplant conditioning [72]. Question: Can you discuss the opportunity for Ziftomenib in combination with FLT3 inhibitors? - Management expressed confidence in the combinability of Ziftomenib with FLT3 inhibitors, citing preclinical data showing strong synergistic effects [58][63]. Question: When could Ziftomenib potentially move into pivotal development? - Management suggested that pivotal studies might not begin until early next year, with ongoing designs being developed based on current data [91]. Question: How does the company view the competitive landscape for menin inhibitors? - Management believes that Ziftomenib's safety and efficacy profile will differentiate it in the market, and they are focused on robust enrollment in ongoing studies [118].

KOMET-001 Phase 1/2 Study of Ziftomenib in Relapsed/Refractory AML Ziftomenib Demonstrates Optimal Pharmaceutical Properties • No dose adjustment of ziftomenib needed when administered with a CYP3A4 inhibitor (e.g., azoles) 10 • Rates of DS in KMT2A-r monotherapy patients were 38.5% at 200 mg and 37.5% at 600 mg; potential to mitigate in combination Fathi et al. EHA 2023 #LB2713 (preliminary data as of April 12, 2023) 11 40% of NPM1 patients achieved a CR during course of study High activity, durable respon ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, INC. (Exact name of Registrant as specified in its Charter) Delaware 61-1547851 (State or other jurisdiction of ...

Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Pete De Spain - Head of Investor Relations Troy Wilson - President & Chief Executive Officer Tom Doyle - Senior Vice President of Finance & Accounting Conference Call Participants Jason Zemansky - Bank of America Peter Lawson - Barclays Roger Song - Jefferies Li Watsek - Cantor Fitzgerald Jeet Mukherjee - BTIG Phil Nadeau - TD Cowen Brad Canino - Stifel Operator Good afternoon, ladies and gent ...

Forecasted Milestones & Financial Highlights 32 | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Corporate Presentation – November 2023 | | | | | * Optimum biologically active dose ** Cash, cash equivalents and short-term investments 2 All forward-looking statements contained in this presentation speak only as of the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Indicate by check mark w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ (State or other jurisdiction ...

Financial Data and Key Metrics Changes - As of June 30, 2023, the company had cash, cash equivalents, and short-term investments of $477 million, an increase from $438 million as of December 31, 2022, which includes net proceeds of approximately $94 million from a public offering completed in June 2023 [15] - The net loss for the second quarter of 2023 was $37.2 million compared to a net loss of $34.8 million for the same period in 2022, with general and administrative expenses rising to $11.8 million from $11.1 million year-over-year [34] Business Line Data and Key Metrics Changes - The company reported a complete remission (CR) rate of 35% and an overall response rate of 45% in patients with NPM1-mutant acute myeloid leukemia (AML) treated with ziftomenib [3] - The median duration of response for all NPM1-mutant patients was 8.2 months, with a median follow-up of 8.8 months [9] Market Data and Key Metrics Changes - NPM1-mutant AML accounts for approximately 30% of new AML cases annually, representing a significant unmet medical need with no approved targeted therapies [4] - Head and neck cancer is the seventh most common cancer worldwide, with a significant unmet medical need for approved small molecule targeted therapies [5] Company Strategy and Development Direction - The company aims to establish ziftomenib as a foundational therapy that can be combined safely with various commonly used regimens, prioritizing combinations that represent the greatest unmet medical need and potential commercial value [142] - The company is evaluating the combination of tipifarnib and alpelisib in head and neck squamous cell carcinoma, with plans to initiate dose expansion in mid-2024 [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the enrollment in the Phase 2 registration-directed trial of ziftomenib, noting that it continues to outperform projections due to strong interest and activity in patients who failed prior treatments [10][19] - Management believes that ziftomenib is well-positioned for the maintenance setting, with a favorable safety profile and no evidence of drug-induced myelosuppression [21][62] Other Important Information - The company plans to begin a post-transplant maintenance program for ziftomenib in the first quarter of 2024 [11] - The company has received FDA clearance for the investigational new drug application for KO-2806 for the treatment of advanced solid tumors, with plans to evaluate its safety and tolerability in a Phase 1 dose escalation study [14] Q&A Session Summary Question: Can you provide more details on enrollment progress for ziftomenib? - Management indicated that they anticipate full enrollment of 85 patients in the study by mid-next year, noting that enrollment is ahead of projections due to physician excitement and the data itself [37][90] Question: What are the expectations for initial data from the combination trial? - Management expects to have preliminary data from the COMET-007 study in the fourth quarter of 2023 or the first quarter of 2024, emphasizing the importance of gathering sufficient data before making meaningful conclusions [137][92] Question: How does the company view resistance mutations in the maintenance setting for ziftomenib? - Management does not believe resistance mutations will significantly impact the use of ziftomenib in the maintenance setting, citing a low rate of resistance mutations observed in their studies [61][62] Question: What is the strategic rationale for starting with renal cell carcinoma (RCC)? - Management explained that RCC is a more mature space with a clear understanding of the landscape, and they have conducted market research to inform their strategy [106] Question: Are there discussions with companies marketing approved drugs for combination therapies? - Management confirmed that they are exploring clinical collaboration or supply agreements to mitigate costs and expedite patient enrollment [121]